TABLE 1.
Patient Characteristics at Baseline
| Characteristic | Squamous n = 30 | Nonsquamous n = 33 | Total N = 63 |
|---|---|---|---|
| Median age, years (range) | 65.5 (46.0–78.0) | 63.0 (39.0–77.0) | 65.0 (39.0–78.0) |
| Male patients, n (%) | 21 (70.0) | 19 (57.6) | 40 (63.5) |
| Race, n (%) | |||
| Caucasian | 20 (66.7) | 25 (75.8) | 45 (71.4) |
| Black | 1 (3.3) | 1 (3.0) | 2 (3.2) |
| Asian | 4 (13.3) | 3 (9.1) | 7 (11.1) |
| Unknown | 1 (3.3) | 4 (12.1) | 5 (7.9) |
| Other | 4 (13.3) | 0 | 4 (6.3) |
| Performance status, n (%) | |||
| 0 | 5 (16.7) | 14 (42.4) | 19 (30.2) |
| 1 | 23 (76.7) | 18 (54.5) | 41 (65.1) |
| 2 | 2 (6.7) | 1 (3.0) | 3 (4.8) |
| Patients with prior antineoplastic therapies, n (%) | 30 (100.0) | 33 (100.0) | 63 (100.0) |
| Type of last therapy, n (%) | |||
| Chemotherapy | 16 (53.3) | 18 (54.5) | 34 (54.0) |
| Targeted therapy | 2 (6.7) | 4 (12.1) | 6 (9.5) |
| Radiotherapy | 10 (33.3) | 5 (15.2) | 15 (23.8) |
| Surgery | 0 | 4 (12.1) | 4 (6.3) |
| Other | 0 | 5 (15.2) | 5 (7.9) |
| Missing | 4 (13.3) | 0 | 4 (6.3) |
| Best response at last therapy, n (%) | |||
| Partial response | 13 (43.3) | 5 (15.2) | 18 (28.6) |
| Stable disease | 5 (16.7) | 16 (48.5) | 21 (33.3) |
| Progressive disease | 9 (30.0) | 9 (27.3) | 18 (28.6) |
| Unknown | 2 (6.7) | 2 (6.1) | 4 (6.3) |
| Not applicable | 1 (3.3) | 1 (3.0) | 2 (3.2) |
| Predominant histology, n (%) | |||
| Adenocarcinoma | 0 | 29 (87.9) | 29 (46.0) |
| Squamous cell carcinoma | 29 (96.7) | 0 | 29 (46.0) |
| Large cell carcinoma | 0 | 3 (9.1) | 3 (4.8) |
| Large cell neuroendocrine carcinoma | 0 | 1 (3.0) | 1 (1.6) |
| Othera | 1 (3.3) | 0 | 1 (1.6) |
| Stage at study entry, n (%) | |||
| Stage IIIA | 1 (3.3) | 0 | 1 (1.6) |
| Stage IIIB | 1 (3.3) | 2 (6.1) | 3 (4.8) |
| Stage IV | 28 (93.3) | 31 (93.9) | 59 (93.7) |
a
Other histologies include large cell endocrine, adenoid, or squamous tumors.